Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium infantis-derived extracellular vesicles
- Development stage
- Preclinical
- Lead developer
- Ewha Womans University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Bifidobacterium infantis-derived extracellular vesicles (B. infantis-EVs) are a microbiome-based therapeutic candidate being investigated for the treatment of inflammatory bowel conditions, specifically non-steroidal anti-inflammatory drug (NSAID)-induced colonic injury. These vesicles are purified from *Bifidobacterium longum* subsp. *infantis* and function by modulating the immune response and restoring gut microbial homeostasis. In preclinical models, B. infantis-EVs have demonstrated the ability to reduce pro-inflammatory cytokines such as IL-1β, IL-2, and TNF-α, while upregulating the anti-inflammatory cytokine TGF-β. Additionally, they help preserve mucosal architecture and promote the growth of beneficial gut microbes like *Akkermansia* and *Lactobacillus*. Research is primarily led by the Ewha Medical Research Institute.
- Other names
- Bifidobacterium longum subsp. infantis-derived extracellular vesicles
02
Targets
IL1B (Interleukin-1 beta)IL-2 (Interleukin 2)TGFB (GARP–latent transforming growth factor beta 1 complex)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on bifidobacterium infantis-derived extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium infantis-derived extracellular vesicles.